Quotables
"For a list of all the ways technology has failed to improve the quality of life, please press three."
Alice Kahn
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8066981 | Compositions and methods related to toll-like receptor-3 The invention relates to compositions and methods related to Toll-like receptor (TLR) polypeptides. In some embodiments, the invention relates to managing TLR3 related diseases. In further embodiments, the invention relates to methods of preventing and treating infl... | 11/29/2011 |
| 7964184 | Cysteine variants of interferon-gamma The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues t... | 06/21/2011 |
| 7959909 | Cysteine variants of interferon gamma The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues t... | 06/14/2011 |
| 7951770 | Peptides, peptidomimetics and small molecule inhibitors of the Epstein-Barr virus mediated fusion and entry process Disclosed are compositions and methods for modulating Epstein-Barr virus (EBV) infection in a patient. The compositions may include peptides or peptidomimetics that are related to gp42 and function to inhibit EBV-mediated membrane fusion. ... | 05/31/2011 |
| 7923432 | Implant depots to deliver growth factors to treat avascular necrosis The present invention relates to the design and composition of a depot implant for optimal delivery of growth factors to treat bone avascular necrosis, in that such depot implant is constructed to be in a cylinder (rod) or sphere shape and have a natural or syntheti... | 04/12/2011 |
| 7871603 | Interferon-beta and/or lambda for use in treating rhinovirus infection in the elderly Use of interferon-beta (IFN-β) and/or IFN-λ for treating rhinovirus (RV) infection in elderly people, particularly elderly people who are, or have been long-term smokers, especially those who have a clinical history of recurrent RV infections, and may have other m... | 01/18/2011 |
| 7803362 | Glycosylated interferon alpha The invention relates to interferon-α molecules having certain O-linked oligosaccharide structures. ... | 09/28/2010 |
| 7727520 | Method of promoting the healing of a chronic wound The present invention provides compositions and methods for promoting the healing of wounds or fibrotic disorders with reduced scarring, comprising inhibitors and inhibiting IFN-γ, together with compositions and methods for promoting the healing of chronic wounds, ... | 06/01/2010 |
| 7449177 | Remedy for pemphigoid An agent for treatment of pemphigoid is provided. For use as an agent for treatment of pemphigoid, IFN-γ is administered in a dose of 2,000,000 JRU once daily for 7 days by intravenous drip infusion. Depending on symptoms, side effects and age of a patient, ... | 11/11/2008 |
| 7445774 | Glycosylated interferon α This invention provides for human interferon-α which includes novel glycosylation structures. ... | 11/04/2008 |
| 7429384 | Chimeric antagonist anth1 A recombinant chimeric antagonist formed by a 60 amino acid fragment of the N-terminal region of human interleukin 2 (IL-2) fused to the N-terminal of the extracellular region of the alpha subunit of the gamma IFN (IFN γ) receptor. In vitro this protein has a T cel... | 09/30/2008 |
| 7371723 | Therapeutic agents comprising pro-apoptotic proteins The present invention relates to targeted killing of a cell utilizing a chimeric polypeptide comprising a cell-specific targeting moiety and a signal transduction pathway factor. In a preferred embodiment, the signal transduction pathway factor is an apoptosis-induc... | 05/13/2008 |
| 7354575 | Method and pharmaceutical composition for treating inflammation A method of treating an inflammation in a subject in need thereof is disclosed. The method comprises locally or systemically administering to the subject IFN-gamma in an amount so as to achieve an IFN-gamma bulk tissue concentration at a site of inflammation of 1-8,... | 04/08/2008 |
| 7338654 | Glycosylated interferon alpha obtained from a transgenic chicken This invention includes compositions comprising glycosylated human interferon-α derived from a chicken. ... | 03/04/2008 |
| 7311924 | Compositions and methods for treating cancer This invention provides compositions and methods for treating neoplasias in a mammal. In particular, the invention provides liposome-encapsulated vinca alkaloids, e.g., vinorelbine, and methods of treating a mammal using such compositions. ... | 12/25/2007 |
| 7300656 | Treatment of inflammatory bowel disease with IFN-gamma inhibitors The invention concerns a method for the prevention or treatment of inflammatory bowel disease by administering an interferon-γ inhibitor. The invention further concerns pharmaceutical compositions and bispecific molecules useful in such method. ... | 11/27/2007 |
| 7300920 | Antiangiogenic peptide agents The current invention provides novel antiangiogenic peptides which correspond to about 133 consecutive amino acids of the N-terminal sequence of growth hormone. ... | 11/27/2007 |
| 7285635 | Modified proteins, designer toxins, and methods of making thereof The present invention concerns methods of reducing the antigenicity of a proteinaceous compound while maintaining the compounds biological activity, as well as proteinaceous compositions with biological activity but reduced antigenicity. These methods and compositio... | 10/23/2007 |
| 7279162 | Isolated broadly reactive opsonic immunoglobulin for treating a pathogenic coagulase-negative staphylococcus infection The invention describes the identification, making, and isolation of immunoglobulin and antigen useful for preventing, diagnosing, and treating staphylococcal infections. The invention further describes an in vivo animal model useful for testing the efficacy of phar... | 10/09/2007 |
| 7273620 | Triggered release of liposomal drugs following mixing of cationic and anionic liposomes Methods and compositions for triggering the delivery of an encapsulated therapeutic agent from a liposome are provided. Liposomes of opposite charge and incorporating lipids which favor non-lamellar structures are contacted in vivo. At least one of the liposome enca... | 09/25/2007 |
| 7247316 | Compositions and methods for treating lymphoma This invention provides methods for treating neoplasias in a mammal. In particular, the invention provides methods for treating various types of lymphomas, including relapsed forms of non-Hodgkin's Lymphoma. These methods involve the administration of liposome-encap... | 07/24/2007 |
| 7244450 | Compositions and methods for treating lymphoma This invention provides methods for treating neoplasias in a mammal. In particular, the invention provides methods for treating various types of lymphomas, including relapsed forms of non-Hodgkin's Lymphoma. These methods involve the administration of liposome-encap... | 07/17/2007 |
| 7238507 | 11 alpha hydroxylase and oxidoreductase The present invention relates to a novel cytochrome P450-like enzyme (Aspergillus ochraceus 11 alpha hydroxylase) and an oxidoreductase (Aspergillus ochraceus oxidoreductase) isolated from cDNA library generated from the mRNA of Aspergillus ochraceu... | 07/03/2007 |
| 7232562 | E38N interferon gamma polypeptide variants A conjugate exhibiting interferon gamma activity and comprising at least one first non-polypeptide moiety covalently linked to an IFG polypeptide, the polypeptide comprising an amino acid sequence that differs from that of a parent IFNG polypeptide in at least one i... | 06/19/2007 |
| 7229623 | Her-2/neu fusion proteins The present invention is generally directed to Her-2/neu fusion proteins, nucleic acid molecules encoding Her-2/neu fusion proteins, viral vectors expressing Her-2/neu fusion proteins, and pharmaceutical compositions (e.g., vaccines) comprising the Her-2/neu fusion ... | 06/12/2007 |
| 7230081 | Interferon gamma conjugates A conjugate exhibiting interferon gamma activity and comprising at least one first non-polypeptide moiety covalently linked to an IFG polypeptide, the polypeptide comprising an amino acid sequence that differs from that of a parent IFNG polypeptide in at least one i... | 06/12/2007 |
| 7229614 | Interferon gamma in the detection and treatment of angiomyolipomas The present invention is directed to methods of treating or preventing angiomyolipomas by administering interferon gamma. It also encompasses methods for assessing the risk of a patient developing angiomyolipomas based upon interferon gamma expression. ... | 06/12/2007 |
| 7205282 | Remedies for hepatitis The object of the present invention is to provide a novel medicinal agent useful in the treatment or the prevention of hepatitis. The present invention is, for example, a therapeutic or preventive agent for hepatitis characterized in that it comprises a compl... | 04/17/2007 |
| 7153499 | Vaccine immunotherapy for immune suppressed patients The present invention provides a formulation for inhibiting metastasis which includes 150–600 units of IL-2, a nonsteroidal anti-inflammatory drug (NSAID), and cyclophosphamide. The present invention further provides a formulation for inhibiting metastasis that in... | 12/26/2006 |
| 7138115 | Use of IL-12 and IL-12 antagonists in the treatment of autoimmune diseases Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one which is promoted by an increase in levels of IFN-γ or TNF-α. Suit... | 11/21/2006 |
| 7129061 | Tumor necrosis factor related ligand The present invention relates to Tumor necrosis factor related ligand (TRELL), a novel member of the tumor necrosis factor family (TNF), modified TRELL, and pharmaceutical compositions comprising them. ... | 10/31/2006 |
| 7115263 | Compositions and methods for treating hyperimmune response in the eye The present invention comprises and utilizes methods and compositions for treating hyperimmune reactions in the eye. Compositions comprising antibodies to gamma interferon alone and in combination with other drugs are described. Also disclosed in the invention are m... | 10/03/2006 |
| 7105156 | Method of using an adenoviral vector encoding a retinoblastoma protein to treat hyperproliferating cells Disclosed are methods of controlling cell cycle progression by introducing into a cell to be controlled a composition selected from the group consisting of p56RB protein, a fragment of the p56RB protein, and the gene encoding p56RB p... | 09/12/2006 |
| 7101977 | Therapeutic agents comprising pro-apoptotic proteins The present invention relates to targeted killing of a cell utilizing a chimeric polypeptide comprising a cell-specific targeting moiety and a signal transduction pathway factor. In a preferred embodiment, the signal transduction pathway factor is an apoptosis-induc... | 09/05/2006 |
| 7083957 | Modified proteins, designer toxins, and methods of making thereof The present invention concerns methods of reducing the antigenicity of a proteinaceous compound while maintaining the compounds biological activity, as well as proteinaceous compositions with biological activity but reduced antigenicity. These methods and compositio... | 08/01/2006 |
| 7084257 | Fully human antibody Fab fragments with human interferon-gamma neutralizing activity Selective binding agents of interferon-gamma (IFNγ) are provided by the invention. More particularly, the invention provides for antibodies and antigen binding domains which selectively bind to IFNγ and may be used to prevent or treat conditions relating to autoim... | 08/01/2006 |
| 7067129 | Receptor specific transepithelial transport in therapeutics The present invention relates in general to methods and products for initiating an immune response against an antigen, and in particular relates to transepithelial delivery of antigens to provoke tolerance and immunity. The present invention further relates to metho... | 06/27/2006 |
| 7060275 | Use of protein biomolecular targets in the treatment and visualization of brain tumors The present invention relates to the use of proteins which are differentially expressed in primary brain tumor tissues, as compared to normal brain tissues, as biomolecular targets for brain tumor treatment therapies. Specifically, the present invention relates to t... | 06/13/2006 |
| 7038015 | Interferon gamma polypeptide variants The present invention relates to novel interferon gamma polypeptide variants having interferon gamma (IFNG) activity, methods for their preparation, pharmaceutical compositions comprising the polypeptide variants and their use in the treatment of diseases, in partic... | 05/02/2006 |
| 7033807 | Aspergillus ochraceus 11 alpha hydroxylase and oxidoreductase The present invention relates to a novel cytochrome P450-like enzyme (Aspergillus ochraceus 11 alpha hydroxylase) and an oxidoreductase (Aspergillus ochraceus oxidoreductase) isolated from cDNA library generated from the mRNA of Aspergillus ochraceu... | 04/25/2006 |
